

## ASX ANNOUNCEMENT

### Benitec Investor Presentation with audio and Q&A

**SYDNEY Australia, 26 September 2013:** Benitec Biopharma (ASX.BLT) is delighted to invite investors to listen to Managing Director and CEO, Dr Peter French and Chief Business Officer, Carl Stubbings as they discuss Benitec's current activities, expected milestones and frequently asked questions during an interview with BRR Media.

This audio webcast is provided to investors in follow up to the recent Benitec road show and summarises the key points covered during investor meetings. To access the presentation, please copy this link into your browser.

<http://www.brrmedia.com/event/116542/>

**For more information please contact:** Dr Peter French | Managing Director and CEO  
Phone: +61 (02) 9555 6986 [pfrench@benitec.com](mailto:pfrench@benitec.com) | [www.benitec.com](http://www.benitec.com)

**About Benitec Biopharma Limited:** Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at [www.benitec.com](http://www.benitec.com).